Board of Directors

Dr. Erich Hunziker

Chairman
read more

Dr. Erich Hunziker

Chairman
« BB Biotech is a strong growth play and it offers a high income stream on top of that »

Erich Hunziker has been on the Board of Directors of BB Biotech AG since 2011 and has been elected president in 2013. He previously served as CFO of Roche from 2001 to 2010. From 1983 to 2001 he held various executive positions at Corange, Boehringer Mannheim and, before joining Roche, at Diethelm-Keller-Gruppe, where he ultimately served as CEO. Erich Hunziker earned a Ph.D. in Industrial Engineering from the Swiss Federal Institute of Technology in Zurich. Dr. Erich Hunziker is Chairman of the Board of Directors of Light Chain Biosciences AG and Entsia International AG and a member of the Board of Directors of LamKap Bio alpha AG, LamKap Bio beta AG and LamKap Bio gamma AG.

Dr. Clive Meanwell

Vice Chairman
read more

Dr. Clive Meanwell

Vice Chairman
« More and more biotech firms are turning a profit. This trend should continue thanks to the full R&D pipelines »

Dr. Clive Meanwell is a member of the Board of Directors of BB Biotech AG since 2003. He is also a member of the Board of Directors and CIO of The Medicines Company, which he established in 1996. From 1995 to 1996 he was a founding partner and managing director of MPM Capital L.P. He previously held various positions at Hoffmann-La Roche in Basel and Palo Alto, California. Dr. Meanwell received his M.D. and Ph.D. from the University of Birmingham in the UK where he also trained in medical oncology.

Prof. Dr. Dr. Klaus Strein

Member
read more

Prof. Dr. Dr. Klaus Strein

Member
« Constant scrutiny of one’s own reasoning and constant effort to close any and all information gaps are the key challenges for us »

Prof. Dr. Dr. Klaus Strein has been on the Board of Directors since 2013. He was with Roche from 1998 to 2011, during which time he held various responsibilities, including head of pharma research activities in Germany and of global pharma research. From 1979 to 1998 he served in various positions at Boehringer Mannheim. He holds post-graduate degrees in chemistry and medicine from the University of Heidelberg, where he was also appointed Adjunct Professor. Prof. Dr. Dr. Klaus Strein is Chairman of the Board of Directors of LamKap Bio alpha AG, LamKap Bio beta AG and LamKap Bio gamma AG and a member of the Board of Directors of NovImmune SA.

Dr. Thomas von Planta

Member
read more

Dr. Thomas von Planta

Member
« A combination of scientific, medical and financial expertise is needed to achieve successful investment results in the biotech sector»

Dr. Thomas von Planta has been elected Board member of BB Biotech in 2019.Since 2006 he is owner / director of CorFinAd AG – Corporate Finance Advisory (M&A transactions and capital market financing). Previously he worked for Bank Vontobel from 2002 to 2006 as Head of Corporate Finance and member of the extended executive board. Prior to that he was with Goldman Sachst from 1992 to 2002 bei Goldman Sachs, ultimately in London in the Equity Capital Markets Group & Investment Banking Division . He holdss a degree in law from the University of Basel and University of Geneva (Dr. iur.), attorney at law. He is also a Board member of Bâloise Holding AG, Basel.